TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...

Nephrolithiasis is an increasingly prevalent disorder in the elderly that is associated with multiple comorbid conditions such as hypertension, coronary artery disease, diabetes and CKD.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Considering taking supplements to treat kidney stones nephrolithiasis? Below is a list of common natural remedies used to treat or reduce the symptoms of kidney stones nephrolithiasis. Follow the ...

Kidney stones (nephrolithiasis) and gout are both common, recurrent, extremely painful conditions, especially in patients ...

Most patients are asymptomatic, but nephrolithiasis is the presenting symptom in about 20% of cases. Overt bone disease in the form of osteitis fibrosa cystica is found in <5% of patients ...

Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News ...

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...